etanercept + methotrexate + rituximab

This is a combination therapy consisting of three agents—etanercept, methotrexate, and rituximab—used primarily in the management of rheumatoid arthritis (RA), particularly in patients with inadequate response to standard therapies. - **Etanercept** is a recombinant dimeric fusion protein that acts as a decoy receptor for tumor necrosis factor alpha (TNF-α), neutralizing its pro-inflammatory effects. - **Methotrexate** is a small molecule antimetabolite and disease-modifying antirheumatic drug (DMARD) that inhibits dihydrofolate reductase, interfering with folic acid metabolism and exerting anti-inflammatory effects through adenosine pathway modulation. - **Rituximab** is a chimeric monoclonal antibody targeting CD20 on B cells, leading to B cell depletion and reduced autoimmune activity. This triple combination may be considered in refractory RA cases but carries increased risk for adverse events such as infections due to profound immunosuppression. The use of multiple biologics together (etanercept + rituximab) with methotrexate is not standard practice due to safety concerns but has been studied in select clinical scenarios[4][10].